Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma

Table 1 Expression of Rho GTPase activating protein 12 in different groups based on clinical pathological features

Clinicopathological features	ARHGAP12 protein expression			t (t-test) or F (ANOVA)	P value
	Number	mean	SD
Age				1.6400	0.1017
> 60	101	5.743	3.504
≤ 60	303	6.342	3.065
Gender				2.1130	0.0352
Male	339	6.046	3.172
Female	65	6.954	3.179
Pathology grade				1.4470	0.2366
Grade I-II	203	6.043	3.347
Grade II-III	85	5.995	3.099
Grade III-IV	113	6.630	2.960
Tumor necrosis				1.5980	0.1112
Yes	178	6.279	2.931
No	80	5.570	3.989
Satellite nodule				0.7686	0.2944
Yes	81	6.079	3.145
No	287	6.199	3.275
Vascular invasion				4.9580	0.0075
M0	199	5.733	3.048
M1	142	6.501	3.217
M2	58	7.062	3.438
TNM stages
T				5.1990	0.0072
T1	45	4.631	3.734
T2	44	7.063	3.982
T3	9	4.000	4.000
N				2.1830	0.0315
N0	96	5.563	4.016
N1	3	10.670	2.309
M				1.5650	0.1208
M0	98	5.653	4.035
M1	1	12.000	0.000
HBV				0.3460	0.7296
HBV-positive	182	6.332	3.626
HBV-negative	62	6.155	3.002

Microvascular invasion grading: M0 level: Microvascular invasion not found; M1 grade: ≤ 5 microvascular invasions and occur in the area of proximal adjacent liver tissue (≤ 1 cm); M2 grade: > 5 microvascular invasions, or microvascular invasions that occur in the area of liver tissue distally adjacent to the cancer (> 1 cm). ARHGAP12: Rho GTPase activating protein 12; TNM: Tumor-node-metastasis; HBV: Hepatitis B virus.